Gene expression
Conversion of a gene's sequence into a mature gene product or products
Follow Gene expression on Notably News to receive short updates to your email — rarely!
We include updates on DNA and RNA codon tables, Messenger RNA, MicroRNA, Transcription factor, Protein biosynthesis, RNA splicing, Lac operon, Stop codon, RNA interference, Polyadenylation, RNA polymerase, Alternative splicing, Quorum sensing, Genomic imprinting, RNA-Seq, Operon ... and more.
| March 2023 |
Genomic imprinting
Viable bipaternal embryos were created.
|
| 2022 |
RNA interference
FDA and EMA approve vutrisiran for treating adults with hereditary transthyretin mediated amyloidosis with polyneuropathy stage 1 or 2.
|
| 2022 |
Genomic imprinting
Parthenogenesis experimentally achieved in mice.
|
| 2020 |
RNA interference
FDA approved lumasiran for the treatment of PH1 (Primary Hyperoxaluria Type 1).
|
| 2020 |
RNA interference
Lumasiran receives approval in both the European Union and United States for treating primary hyperoxaluria type 1 (PH1) in pediatric and adult populations.
|
| 2020 |
RNA interference
Inclisiran receives approval in Europe with anticipated US approval in 2021.
|
| December 2020 |
RNA interference
Novartis announced positive phase III efficacy study results for inclisiran as a treatment for heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD).
|
| November 2019 |
RNA interference
FDA grants givosiran breakthrough therapy designation, priority review designation, and orphan drug designation for treating acute hepatic porphyria (AHP).
|
| 2018 |
RNA interference
FDA approved patisiran, the first siRNA-based drug.
|
| 2018 |
RNA interference
Patisiran becomes the first double-stranded siRNA-based medication approved, developed by Alnylam Pharmaceuticals to suppress the TTR gene responsible for hereditary ATTR amyloidosis.
|
| 2018 |
Genomic imprinting
Genome editing allowed for creation of bipaternal and viable bimaternal mouse embryos.
|
| 2012 | The existence of backsplicing was first suggested, explaining the genesis of circular RNAs through a specific exonic junction mechanism where the 3' boundary of an exon connects with the 5' boundary of an upstream exon. |
| 2010 |
RNA interference
First-in-human Phase I clinical trial started, using a nanoparticle delivery system to target solid tumors.
|
This contents of the box above is based on material from the Wikipedia articles RNA splicing, Genomic imprinting & RNA interference, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.